ClinicalTrials.gg
RecruitingNCT07161869POELH-IIIUpdated Sep 10, 2026

Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)

An observational study in Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma (Icc) and Cholangiocarcinoma, sponsored by Erasmus Medical Center. Recruiting at 6 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Erasmus Medical Center · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Study summary

In the POELH-II trial (Clinicaltrials.gov ID NCT05678218) patients with presumed resectable perihilar (pCCA), intrahepatic (iCCA) or mid-common bile duct (CBD) cholangiocarcinoma had the outcomes of their preoperative endoscopic ultrasound (EUS) registered. This EUS procedure was done systematically, targeting lymph nodes (LNs) with the aim to identify LN metastases preoperatively.

The goal of this follow-up observational cohort study (POELH-III) is to assess the yield of preoperative EUS, with an improved EUS approach. The EUS protocol as used in the POELH-II trial was improved based on preliminary results of the POELH-II trial. The main questions it aims to answer is:

- The number of patients precluded from surgical work-up due to positive regional or extraregional LNs identified by EUS guided tissue acquisition

02

Conditions studied

  • Hilar Cholangiocarcinoma
  • Intrahepatic Cholangiocarcinoma (Icc)
  • Cholangiocarcinoma
  • Perihilar Cholangiocarcinoma
  • Common Bile Duct Neoplasms
  • Adenocarcinoma of Biliary Tract

Keywords

  • poelh
  • EUS
  • Lymph node
  • cholangiocarcinoma
  • biliary tract cancer
03

In context

Klatskin Tumor

82 studies on the registry are indexed under Klatskin Tumor; 27 are open to participants now.

This study's planned enrollment of 250 is above the median of 200 across 23 observational studies indexed under Klatskin Tumor.

Browse Klatskin Tumor studies →

Lead sponsor

Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with suspected iCCA or pCCA who have a presumed resectable carcinoma will be invited to participate. Patients with CCA distal from the cystic junction but proximal from the pancreatic body are eligible for inclusions as well, as treatment is similar to Bismuth I pCCA. In other words, all patients with CCA that is not distal CCA for which a pancreato-duodenectomy is indicated, are eligible for inclusion. Also patients with presumed unresectable pCCA who are worked-up for liver transplantation are invited to participate. At time of inclusion a definitive diagnosis of iCCA/pCCA is not obligatory, since definitive diagnosis of CCA is sometimes confirmed during the preoperative EUS through EUS guided biopsy of the mass. The probable diagnosis of iCCA/pCCA and the suspected resectability will be established during the multidisciplinary meeting, based on clinical symptoms, cross-sectional imaging, endoscopy and laboratory tests.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presumed resectable pCCA OR
  • Presumed resectable iCCA OR
  • Presumed resectable mid-common bile duct CCA OR
  • Presumed unresectable pCCA worked-up for Liver Transplantation AND
  • Written must be given according to International Council on Harmonisation/Good Clinical Practice guidelines, and national/local regulations AND
  • Age > 18 years.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of treated CCA
  • Patients with CCA for which a pancreatoduodenectomy is indicated, based on cross-sectional imaging
  • Patients with a history of treated liver
  • Patients with a for EUS-tissue acquisition (f.e. uncorrectable coagulopathy or disorder), in line with current clinical practice
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Presumed resectable perihilar, intrahepatic or mid-common bile duct (CBD) cholangiocarcinoma

    Procedure: Registration of all findings during preoperative Endoscopic Ultrasound

Interventions

  • ProcedureRegistration of all findings during preoperative Endoscopic Ultrasound

    Using the improved POELH-III EUS format

06

What researchers measure

Primary outcomes

  1. The number of patients precluded from surgical work-up due to positive regional or extraregional lymph nodes identified by endoscopic ultrasound guided tissue acquisition

    Time frame: Through study completion, max 1 year

Secondary outcomes

  1. Short term and long term complications of the EUS (+/- tissue acquisition) procedure

    Short term (\<30 days) * Sedation related: consisting of cardiovascular-related complications (cardiac arrhythmias, myocardial ischemia/infarction), respiratory- related complications (respiratory depression, hypoxia, airway obstruction, pulmonary aspiration of gastric contents) and allergic reactions. * Hemorrhage (outside peritoneal wall): defined as clinical evidence of bleeding with a hemoglobin drop of \>3g/dl with the need for resuscitation or additional intervention * Perforation: defined as evidence of air or luminal contents outside the gastro-intestinal tract together with clinical symptoms, requiring percutaneous drainage or surgery * Mortality Long term (\>30 days) \- Tumor seeding; defined as proof of carcinoma in the biopsy tract during follow-up or at autopsy

    Time frame: Through study completion, max 1 year

07

Study locations

1 of 6 sites recruiting
  • Erasmus MC University Medical Center
    Rotterdam, South Holland 3015 CN, Netherlands
    Recruiting
    • Lydi MJW van Driel, MD PhD · Principal investigator
    • Marco J Bruno, MD PhD · Sub investigator
    • Bas Groot Koerkamp, MD PhD · Sub investigator
    • David M de Jong, MD MSc · Sub investigator
  • Amsterdam University Medical Center
    Amsterdam, Netherlands
    Not yet recruiting
    • Rogier P Voermans, MD PhD · Principal investigator
  • University Medical Center Groningen
    Groningen, Netherlands
    Not yet recruiting
    • Frederike GI van Vilsteren, MD PhD · Principal investigator
    • Wouter Nagengast, MD PhD · Sub investigator
  • Leiden University Medical Center
    Leiden, Netherlands
    Not yet recruiting
    • Akin Inderson, MD · Principal investigator
  • Maastricht University Medical Center+
    Maastricht, Netherlands
    Not yet recruiting
    • Jan Werner Poley, MD PhD · Principal investigator
    • Maxime Dewulf, MD PhD · Sub investigator
  • University Medical Center Utrecht
    Utrecht, Netherlands
    Not yet recruiting
    • Joep de Bruijne, MD PhD · Principal investigator
08

References and documents

Publications

  • de Jong DM, van de Vondervoort S, Dwarkasing RS, Thomeer MGJ, Doukas M, Voermans RP, Verdonk RC, Polak WG, de Jonge J, Bruno MJ, Van Driel LMJW, Groot Koerkamp B. Endoscopic ultrasound with tissue acquisition of lymph nodes in patients with potentially resectable intrahepatic cholangiocarcinoma. Endosc Int Open. 2024 Aug 23;12(8):E998-E1005. doi: 10.1055/a-2366-2592. eCollection 2024 Aug. PubMed 39184062 ↗
  • Larghi A, Rimbas M, Ardito F, Rizzatti G, Giuliante F. Letter to the Editor: EUS-FNA for Lymph Nodes Staging in Cholangiocarcinoma: Should It Become Standard of Care? Hepatology. 2020 Oct;72(4):1496. doi: 10.1002/hep.31266. No abstract available. PubMed 32277489 ↗
  • Malikowski T, Levy MJ, Gleeson FC, Storm AC, Vargas EJ, Topazian MD, Abu Dayyeh BK, Iyer PG, Rajan E, Gores GJ, Roberts LR, Chandrasekhara V. Endoscopic Ultrasound/Fine Needle Aspiration Is Effective for Lymph Node Staging in Patients With Cholangiocarcinoma. Hepatology. 2020 Sep;72(3):940-948. doi: 10.1002/hep.31077. Epub 2020 Jul 9. PubMed 31860935 ↗
  • Gleeson FC, Rajan E, Levy MJ, Clain JE, Topazian MD, Harewood GC, Papachristou GI, Takahashi N, Rosen CB, Gores GJ. EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc. 2008 Mar;67(3):438-43. doi: 10.1016/j.gie.2007.07.018. Epub 2007 Dec 3. PubMed 18061597 ↗
  • de Jong DM, den Hoed CM, Willemssen FEJA, Thomeer MGJ, Bruno MJ, Koerkamp BG, de Jonge J, Alwayn IPJ, van Hooft JE, Hoogwater F, van der Heide F, Inderson A, van Vilsteren FGI, van Driel LMJW. Impact of EUS in liver transplantation workup for patients with unresectable perihilar cholangiocarcinoma. Gastrointest Endosc. 2024 Apr;99(4):548-556. doi: 10.1016/j.gie.2023.10.047. Epub 2023 Oct 27. PubMed 37890597 ↗
  • de Jong DM, van de Vondervoort S, Dwarkasing RS, Doukas M, Voermans RP, Verdonk RC, Polak WG, de Jonge J, Koerkamp BG, Bruno MJ, van Driel LMJW. Endoscopic ultrasound in patients with resectable perihilar cholangiocarcinoma: impact on clinical decision-making. Endosc Int Open. 2023 Feb 2;11(2):E162-E168. doi: 10.1055/a-2005-3679. eCollection 2023 Feb. PubMed 36741342 ↗
  • de Jong DM, Lammers WJ, van Driel LMJW. Time to standardize preoperative EUS for lymph node staging in resectable extrahepatic cholangiocarcinoma. J Hepatol. 2025 Dec;83(6):e290-e291. doi: 10.1016/j.jhep.2025.06.031. Epub 2025 Jul 9. No abstract available. PubMed 40645595 ↗

Individual participant data

Plan to share: Undecided — Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Oct 2028, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 9, 2025
StartActual
Feb 5, 2026
Primary completionEst.
Oct 1, 2028
CompletionEst.
Nov 1, 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07161869
Responsible party
Lydi M.J.W. van Driel, MD, MSc, PhD (Principal Investigator, Erasmus Medical Center) — Principal investigator
First posted
Sep 9, 2025
Start date
Feb 5, 2026
Primary completion
Oct 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Lydi M. J. W. van Driel, MD PhD
Contact
l.m.j.w.vandriel@erasmusmc.nl
+ 31 10 704 0704
David M de Jong, MD MSc
Contact
d.m.dejong@erasmusmc.nl

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion